Investor Presentaiton

Key Business Performance ✓ Herzuma®, a leading trastuzumab biosimilar in Europe, started to go direct in 2H22 HerzumaⓇ ✓ Surpassed the market share of HerceptinⓇ in Japan & Increasing demands in LATAM boosted the sales growth M/S of HerzumaⓇ in Europe 1% 10% M/S of HerzumaⓇ in Japan 19% 16% 15% 15% 14% 14% 13% 25% 19.08 approval of 3-weekly regimen 2% 0% 12% 50% 51% 53% 54% 55% 46% 44% 39% 35% 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q Herzuma® HerceptinⓇ E Biosimilar F Biosimilar G Biosimilar Note: The market share is based on volume Source: IQVIA HerzumaⓇ Note: The market share is based on volume Source: IQVIA HerceptinⓇ Investor Relations 2022 12

View entire presentation